Parameswaran Venugopal to Lymphoma, Non-Hodgkin
This is a "connection" page, showing publications Parameswaran Venugopal has written about Lymphoma, Non-Hodgkin.
Connection Strength
1.301
-
Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients. Cancer. 2011 Apr 01; 117(7):1490-7.
Score: 0.382
-
Relapsed non-Hodgkin lymphoma in fraternal twins managed successfully with rituximab maintenance therapy. Clin Adv Hematol Oncol. 2005 Feb; 3(2):136-9; discussion 139-40.
Score: 0.256
-
Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma. Br J Haematol. 2019 07; 186(1):45-53.
Score: 0.171
-
Impact of cachexia on outcomes in aggressive lymphomas. Ann Hematol. 2017 Jun; 96(6):951-956.
Score: 0.149
-
Bendamustine and Rituximab: Complete Response in a 62-Year-Old Female with an Aggressive Lymphoma and an Ejection Fraction of 20. Chemotherapy. 2017; 62(2):140-146.
Score: 0.146
-
Posttransplant lymphoproliferative disorder: extranodal marginal zone lymphoma occurring after renal transplantation. Clin Adv Hematol Oncol. 2006 Aug; 4(8):600-4; discussion 604-6.
Score: 0.071
-
The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade Non-Hodgkin's lymphoma. Clin Lymphoma. 2005 Jun; 6(1):26-30.
Score: 0.066
-
Autologous stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin's lymphoma. Clin Adv Hematol Oncol. 2004 Apr; 2(4):229-33.
Score: 0.060